Trial Profile

A first-in-human Phase 1 single ascending dose trial assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-2138 in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATI 2138 (Primary) ; ATI 2138
Indications Psoriasis
Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
Sponsors Aclaris Therapeutics

Most Recent Events

12 Feb 2025 Results published in the Aclaris Therapeutics Media Release.
12 Feb 2025 According to an Aclaris Therapeutics media release, data from this study was published in The Journal of Pharmacology and Experimental Therapeutics.
08 Nov 2022 Results are presented in an Aclaris Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com